Methylnaltrexone Bromide (MNTX) + Placebo
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Colonic Inertia
Conditions
Colonic Inertia
Trial Timeline
Sep 1, 2009 → Dec 1, 2011
NCT ID
NCT00949377About Methylnaltrexone Bromide (MNTX) + Placebo
Methylnaltrexone Bromide (MNTX) + Placebo is a approved stage product being developed by Pfizer for Colonic Inertia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00949377. Target conditions include Colonic Inertia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00949377 | Approved | Withdrawn |
Competing Products
6 competing products in Colonic Inertia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzastaurin HCl | Eli Lilly | Phase 2 | 52 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 52 |
| Indium labeled IMP-205xm734 | Gilead Sciences | Phase 1 | 32 |
| psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo) | Pfizer | Pre-clinical | 22 |
| oxaliplatin | Sanofi | Approved | 84 |
| Oxaliplatin (SR96669) | Sanofi | Phase 3 | 76 |